Market Closed -
Japan Exchange
11:30:00 02/05/2024 am IST
5-day change
1st Jan Change
120
JPY
-1.64%
+0.84%
-14.29%
3-D Matrix, Ltd. signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.
3-D Matrix, Ltd. (JASDAQ:7777) signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd. on August 3, 2021. As part of the transaction, 3-D Matrix, Ltd. will transfer patent and license to PURMX Therapeutics Co., Ltd.
3-D Matrix, Ltd. announced that it has received ¥22.62 million in funding from CVI Investments, Inc.
04/04
CI
3-D Matrix, Ltd. announced that it expects to receive ¥22.62 million in funding from CVI Investments, Inc.
19/03
CI
3-D Matrix, Ltd.(TSE:7777) dropped from S&P Global BMI Index
18/23/18
CI
3-D Matrix, Ltd. announced that it has received ¥686.237876 million in funding from CVI Investments, Inc.
18/23/18
CI
3-D Matrix, Ltd. announced that it expects to receive ¥686.237876 million in funding from CVI Investments, Inc.
29/23/29
CI
3-D Matrix, Ltd. announced that it has received ¥508.76 million in funding from CVI Investments, Inc.
16/23/16
CI
3-D Matrix, Ltd. announced that it expects to receive ¥508.76 million in funding from CVI Investments, Inc.
28/23/28
CI
3-D Matrix, Ltd. announced that it has received ¥2.059835568 billion in funding from CVI Investments, Inc.
17/22/17
CI
3-D Matrix, Ltd. announced that it expects to receive Ã2.059835568 billion in funding from CVI Investments, Inc.
30/22/30
CI
3-D Matrix, Ltd. Auditor Raises 'Going Concern' Doubt
28/22/28
CI
3-D Matrix, Ltd. announced that it has received ¥1.77192847 billion in funding from CVI Investments, Inc.
27/22/27
CI
3-D Matrix, Ltd. announced that it expects to receive ¥1.77192847 billion in funding from CVI Investments, Inc.
11/22/11
CI
3-D Matrix, Ltd. announced that it has received ¥2.609 billion in funding from CVI Investments, Inc.
27/21/27
CI
3-D Matrix, Ltd. announced that it expects to receive ¥2.609 billion in funding from CVI Investments, Inc.
11/21/11
CI
3-D Matrix, Ltd. signed contract to acquire 10% stake in PURMX Therapeutics Co., Ltd.
03/21/03
CI
3-D Matrix, Ltd. Announces Board Appointments
02/21/02
CI
3-D Matrix, Ltd. announced that it has received ¥216.0702 million in funding from CVI Investments, Inc.
26/20/26
CI
3-D Matrix, Ltd. announced that it expects to receive ¥216.0702 million in funding from CVI Investments, Inc.
10/20/10
CI
3-D Matrix, Ltd. announced that it has received ¥12.8 million in funding from CVI Investments, Inc.
10/20/10
CI
3-D Matrix, Ltd. announced that it expects to receive ¥12.8 million in funding from CVI Investments, Inc.
20/19/20
CI
3-D Matrix, Ltd. announced that it has received ¥1.31202 billion in funding from CVI Investments, Inc.
15/19/15
CI
3-D Matrix, Ltd. announced that it expects to receive ¥1.31202 billion in funding from CVI Investments, Inc.
29/19/29
CI
3-D Matrix, Ltd. announced that it has received ¥17.055 million in funding from SMBC Nikko Securities Inc., Investment Arm
17/18/17
CI
3-D Matrix, Ltd. announced that it expects to receive ¥17.055 million in funding from SMBC Nikko Securities Inc., Investment Arm
28/18/28
CI
3-D Matrix, Ltd. announced that it has received ¥885.0474 million in funding
20/17/20
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.
More about the company
1st Jan change
Capi.
-14.29% 64.07M +25.69% 47.9B +47.41% 41.42B -3.46% 40.7B -6.20% 28.92B +9.17% 25.55B -20.42% 19.27B +0.17% 12.15B +28.07% 12.14B -1.24% 11.99B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1